Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy

Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) over a 12-month period after switching from interleukin (IL)-6 receptor inhibitors (iIL6R) for non-medical reasons.Material and methods. A retrospective cohort study conducted in 11 cente...

Full description

Saved in:

Bibliographic Details
Main Authors:	P. A. Shesternya, A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Yu. Yu. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, A. A. Blinova, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, N. V. Yudina, E. N. Alekseev, E. L. Nasonov, A. M. Lila
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2024-10-01
Series:	Современная ревматология
Subjects:	rheumatoid arthritis real-world clinical practice interleukin-6 inhibitor olokizumab monotherapy biological therapy administrative switch
Online Access:	https://mrj.ima-press.net/mrj/article/view/1640
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy

Similar Items